Dr. Salz has 6 yrs of FDA regulatory experience in reviewing the Chemistry, Manufacturing, and Controls (CMC) information supporting development of cell and gene therapies (CBER/OTP) (2016-2022). She is currently a Senior Practice Expert at Dark Horse Consulting Group where she advises clients on development of cell and gene therapies. Tal Salz earned a PhD from the University of Florida, and performed a post-doctoral research at Johns Hopkins University.